Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab cardiovascular outcomes study in dialysis-dependent end-stage kidney disease
CTR20244496Phase 3Active
- Sponsor
- CSL Limited
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of clazakizumab in end-stage kidney disease (ESKD), atherosclerotic disease, type 2 diabetes mellitus (T2DM), chronic inflammation, sponsored by CSL Limited. Started Apr 2025; status: active.
02
Drugs
clazakizumab
03
Conditions
end-stage kidney disease (ESKD)atherosclerotic diseasetype 2 diabetes mellitus (T2DM)chronic inflammation
Beyond the preview
Go deeper on CTR20244496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244496.